Tonix makes two new hires
This article was originally published in Scrip
Tonix Pharmaceuticals, a US company developing drugs for central nervous system disorders, has appointed Dr Leland Gershell as chief financial officer and Dr Bruce Daugherty in the newly created position as senior director of drug development. Benjamin Selzer, who served as interim chief financial officer, will continue as the company's chief operating officer. Dr Gershell most recently served as managing director and senior analyst at Madison Williams and Company, where he provided research on specialty pharmaceutical and biotechnology companies, while Dr Daugherty has more than 30 years' experience in drug development and scientific research, mostly with Merck & Co, where he most recently served as senior research fellow.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.